Skip to main content

Advertisement

Table 4 Multivariate analysis for the prognostic impact of IDH mutations, PTEN deletion, MGMT methylation and EGFR amplification

From: Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation

  N Median Survival (MS-months) N Multivariate analysisa
Hazard ratio 95% Cl p-Value
GBM
IDH
  Mutant 10 25.0 10 0.52 0.24–1.11 0.092
  Wildtype 241 10.0 230   Reference  
Astrocytoma
IDH
  Mutant 42 14.0 33 0.22 0.11–0.43 < 0.001
  Wildtype 52 114.0 46   Reference  
GBM IDH-wildtype
PTEN
  Deleted 184 11.0 171 0.65 0.43–0.99 0.042
  Non-Deleted 38 6.0 34   Reference  
MGMT
  Methylated 52 12.0 46 0.61 0.42–0.88 0.009
  Unmethylated 180 9.0 159   Reference  
EGFR
  Amplified 88 11.0 82 0.88 0.65–1.18 0.393
  Non- Amplified 135 8.0 123   Reference  
Astrocytoma IDH-wildtype
PTEN
  Deleted 18 8.0 14 4.48 1.34–14.94 0.015
  Non-deleted 17 29.0 11   Reference  
MGMT
  Methylated 9 3.0 7 0.69 0.20–2.4 0.555
  Unmethylated 31 16.0 18   Reference  
EGFR
  Amplified 14 14.0 12 0.71 0.25–2.03 0.522
  Non- Amplified 20 13.0 13   Reference  
  1. aMultivariate analysis was performed controlling the following independent variables: age, gender, treatment